APA (7th ed.) Citation

CL, R., CN, A., & MF, M. (2021). NM101 Phase III study of NE3107 in Alzheimer's disease: Rationale, design and therapeutic modulation of neuroinflammation and insulin resistance. Neurodegenerative disease management, 11(4), 289. https://doi.org/10.2217/nmt-2021-0022

Chicago Style (17th ed.) Citation

CL, Reading, Ahlem CN, and Murphy MF. "NM101 Phase III Study of NE3107 in Alzheimer's Disease: Rationale, Design and Therapeutic Modulation of Neuroinflammation and Insulin Resistance." Neurodegenerative Disease Management 11, no. 4 (2021): 289. https://doi.org/10.2217/nmt-2021-0022.

MLA (9th ed.) Citation

CL, Reading, et al. "NM101 Phase III Study of NE3107 in Alzheimer's Disease: Rationale, Design and Therapeutic Modulation of Neuroinflammation and Insulin Resistance." Neurodegenerative Disease Management, vol. 11, no. 4, 2021, p. 289, https://doi.org/10.2217/nmt-2021-0022.